Department of Respiratory Medicine Children's Hospital of Chongqing Medical University, Chongqing, China.
National Clinical Research Center for Child Health and Disorders, Chongqing, China.
JAMA Pediatr. 2022 Dec 1;176(12):1199-1207. doi: 10.1001/jamapediatrics.2022.4123.
Short-course antibiotic therapy could enhance adherence and reduce adverse drug effects and costs. However, based on sparse evidence, most guidelines recommend a longer course of antibiotics for nonsevere childhood community-acquired pneumonia (CAP).
To determine whether a shorter course of antibiotics was noninferior to a longer course for childhood nonsevere CAP.
MEDLINE, Embase, Web of Science, the Cochrane Library, and 3 Chinese databases from inception to March 31, 2022, as well as clinical trial registries and Google.com.
Randomized clinical trials comparing a shorter- vs longer-course therapy using the same oral antibiotic for children with nonsevere CAP were included.
Random-effects models were used to pool the data, which were analyzed from April 15, 2022, to May 15, 2022. Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to rate the quality of the evidence.
Treatment failure, defined by persistence of pneumonia or the new appearance of any general danger signs of CAP (eg, lethargy, unconsciousness, seizures, or inability to drink), elevated temperature (>38 °C) after completion of treatment, change of antibiotic, hospitalization, death, missing more than 3 study drug doses, loss to follow-up, or withdrawal of informed consent.
Nine randomized clinical trials including 11 143 participants were included in this meta-analysis. A total of 98% of the participants were aged 2 to 59 months, and 58% were male. Eight studies with 10 662 patients reported treatment failure. Treatment failure occurred in 12.8% vs 12.6% of participants randomized to a shorter vs a longer course of antibiotics. High-quality evidence showed that a shorter course of oral antibiotic was noninferior to a longer course with respect to treatment failure for children with nonsevere CAP (risk ratio, 1.01; 95% CI, 0.92-1.11; risk difference, 0.00; 95% CI, -0.01 to 0.01; I2 = 0%). A 3-day course of antibiotic treatment was noninferior to a 5-day course for the outcome of treatment failure (risk ratio, 1.01; 95% CI, 0.91-1.12; I2 = 0%), and a 5-day course was noninferior to a 10-day course (risk ratio, 0.87; 95% CI, 0.50-1.53; I2 = 0%). A shorter course of antibiotics was associated with fewer reports of gastroenteritis (risk ratio, 0.79; 95% CI, 0.66-0.95) and lower caregiver absenteeism (incident rate ratio, 0.74; 95% CI, 0.65-0.84).
Results of this meta-analysis suggest that a shorter course of antibiotics was noninferior to a longer course in children aged 2 to 59 months with nonsevere CAP. Clinicians should consider prescribing a shorter course of antibiotics for the management of pediatric nonsevere CAP.
短期疗程的抗生素治疗可以提高依从性,减少药物不良反应和成本。然而,基于有限的证据,大多数指南建议对非严重儿童社区获得性肺炎(CAP)使用更长疗程的抗生素。
确定较短疗程的抗生素是否与较长疗程的抗生素治疗非严重儿童 CAP 一样有效。
从建库到 2022 年 3 月 31 日,检索 MEDLINE、Embase、Web of Science、Cochrane 图书馆和 3 个中文数据库,以及临床试验注册库和 Google.com。
纳入比较使用相同口服抗生素治疗非严重 CAP 的儿童的较短疗程与较长疗程的随机临床试验。
使用随机效应模型对数据进行汇总,分析时间为 2022 年 4 月 15 日至 2022 年 5 月 15 日。采用推荐评估、制定与评价(GRADE)分级来评估证据质量。
治疗失败,定义为肺炎持续存在或 CAP 出现任何新的一般危险体征(如昏睡、昏迷、癫痫发作或无法饮水),治疗完成后体温升高(>38°C),抗生素更换,住院,死亡,漏服超过 3 次研究药物,失访或撤回知情同意。
这项荟萃分析纳入了 9 项随机临床试验,共 11433 名参与者。参与者的年龄均为 2 至 59 个月,98%,其中 58%为男性。8 项研究共 10662 名患者报告了治疗失败。随机接受较短疗程和较长疗程抗生素治疗的参与者中,治疗失败的发生率分别为 12.8%和 12.6%。高质量证据表明,对于非严重 CAP 儿童,较短疗程的口服抗生素与较长疗程的抗生素相比,在治疗失败方面非劣效(风险比,1.01;95%置信区间,0.92-1.11;风险差异,0.00;95%置信区间,-0.01 至 0.01;I2=0%)。3 天疗程的抗生素治疗与 5 天疗程的治疗失败非劣效(风险比,1.01;95%置信区间,0.91-1.12;I2=0%),5 天疗程与 10 天疗程非劣效(风险比,0.87;95%置信区间,0.50-1.53;I2=0%)。较短疗程的抗生素治疗与较少报告的肠胃炎(风险比,0.79;95%置信区间,0.66-0.95)和较低的护理人员缺勤率(发生率比,0.74;95%置信区间,0.65-0.84)相关。
这项荟萃分析的结果表明,对于 2 至 59 个月大的非严重 CAP 儿童,较短疗程的抗生素与较长疗程的抗生素一样有效。临床医生应考虑为儿童非严重 CAP 管理开具较短疗程的抗生素。